Get the Stockscreener App
0.189
10.53%
0.018
After Hours:
.18
-0.009
-4.76%
Silexion Therapeutics Corp stock is traded at $0.189, with a volume of 2.70M.
It is up +10.53% in the last 24 hours and down -44.41% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$0.171
Open:
$0.1707
24h Volume:
2.70M
Relative Volume:
1.87
Market Cap:
$2.74M
Revenue:
Net Income/Loss:
$-12.91M
P/E Ratio:
-0.002
EPS:
-94.5617
Net Cash Flow:
$-12.02M
1W Performance:
-19.54%
1M Performance:
-44.41%
6M Performance:
-98.15%
1Y Performance:
-99.50%
1-Day Range:
$0.1675
$0.195
1-Week Range:
$0.163
$0.232
52-Week Range:
$0.163
$38.20
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.189 | 2.74M | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Form DEF 14A SILEXION THERAPEUTICS CORP For: 12 October By Investing.com - Investing.com UK
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire Inc.
Silexion cuts warrant price to raise $840K in cash infusion - Dealroom
Silexion Therapeutics Announces Warrant Inducement Financing Deal - The Globe and Mail
Silexion Therapeutics Announces Warrant Inducement Financing Deal - TipRanks
Form 8K Silexion Therapeutics Corp For: 29 September By Investing.com - Investing.com UK
A cash deal at Silexion (SLXN) comes with rights to buy up to 6.4 million more shares. - Stock Titan
Silexion raises $837,000 through warrant exercise at reduced price - Investing.com
Silexion Therapeutics Announces Exercise of Warrants - GlobeNewswire
Silexion Therapeutics Corp. Announces Immediate Exercise of Series E Warrants and Issuance of New Warrants in $837,366 Financing - Quiver Quantitative
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com Canada
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - The Globe and Mail
Silexion Therapeutics Shareholders Reject Capital Structure Changes - The Globe and Mail
Silexion Therapeutics Notified of Nasdaq Bid Price Deficiency, Trading Continues Unaffected - Kalkine Media
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Why Is the Market Watching Silexion Therapeutics (SLXN)? - kalkinemedia.com
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - vinanet.vn
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - TipRanks
Silexion Therapeutics Received Notice of Delisting - TradingView
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Quiver Quantitative
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Executes Reverse Share Split Amid Strain - TipRanks
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com India
Silexion Therapeutics Closes Public Offering and Strengthens Equity - TipRanks
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Canada
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com UK
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants | slxn Stock News - Quiver Quantitative
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com India
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com Australia
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):